Sierra Oncology

Next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer

Sierra Oncology (NASDAQ: SRRA) [formerly ProNAi Therapeutics (NASDAQ: DNAI)] is a clinical stage company advancing a pipeline of promising therapies that target the DNA Damage Response (DDR) network. The company’s lead drug candidate, SRA737, is a highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), which is a key cell cycle checkpoint and central regulator of the DDR network. Sierra Oncology is also advancing SRA141, a potent, selective and orally bioavailable small molecule inhibitor of the Cdc7 kinase, which is a key regulator of both DNA replication and the DDR network, in preclinical development.

Status

IPO in 2015 (NASDAQ: SRRA)

Year of Investment

2014

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Vancouver, British Columbia